Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NGFR | P08138 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420814 | 0.87 | HTR1A (0.45) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL22048826 | 0.87 | MAPT (0.46) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL5384431 | 0.85 | NPC1 (0.38) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL532721 | 0.85 | NPC1 (0.38) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL889790 | 0.84 | PLK4 (0.41) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL533320 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL22062297 | 0.83 | PLK4 (0.46) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL8205463 | 0.80 | MAPK1 (0.60) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL4294423 | 0.76 | KDM4E (0.48) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL13497870 | 0.74 | ALDH1A1 (0.48) | KDM4EALDH1A1LMNAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080894-A1 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION | 2014-03-20 | — | — | US | claimed |
| CN-103476947-A | Enhanced biodistribution of oligomers | GROOVE BIOPHARMA CORP | 2013-12-25 | — | — | CN | claimed |
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | claimed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| EP-1789582-B1 | NEISSERIA GONORRHOEAE DETECTION USING THE 5' UNTRANSLATED REGION OF THE OPA GENE | JEROEN BOSCH ZIEKENHUIS (NL) | 2010-10-06 | — | — | EP | claimed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | claimed |
| US-20100228017-A1 | OLIGONUCLEOTIDES CONTAINING PYRAZOLO[3,4-D] PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION | ELITECH HOLDING B.V. (NL) | 2010-09-09 | — | — | US | claimed |
| EP-1144429-B1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES INC (US) | 2009-07-15 | — | — | EP | claimed |
| US-7556923-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-20080003591-A1 | Neisseria Gonorrhoeae Detection Using the 5' Untranslated Region of the Opa Gene | JEROEN BOSCH ZIEKENHUIS (NL) | 2008-01-03 | — | — | US | claimed |
| US-6972328-B2 | Non-aggregating non-quenching oligomer comprising nucelotide analogs, method of synthesis and use thereof | EPOCH BIOSCIENCES, INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-6884584-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2005-04-26 | — | — | US | claimed |
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DRUG ROYALTY LP1 (CA) | 2005-03-24 | — | — | US | claimed |
| US-20040058322-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | US | claimed |
| US-6492346-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | claimed |
| US-12516384-B2 | Methods and kit for analyzing responsiveness of patients to CD19 immunotherapy | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-0819133-A2 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | EPOCH PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996032496-A2 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | MICROPROBE CORPORATION (US) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | KDM4E 2995/4885ALDH1A1 1779/4885LMNA 2558/4885 |
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DDB1, LIG3, MSH2 | KDM4E 4454/4885ALDH1A1 4598/4885LMNA 3853/4885 |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | KDM4E 4454/4885ALDH1A1 4598/4885LMNA 3853/4885 |
| US-20100228017-A1 | OLIGONUCLEOTIDES CONTAINING PYRAZOLO[3,4-D] PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION | DPYD, DTYMK, TYMP | KDM4E 4475/4885ALDH1A1 3117/4885LMNA 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.